Last updated: February 19, 2026
Summary
Canadian patent CA2767971, titled "Antiviral Compounds," claims a genus of substituted pyrimidine compounds and specific pharmaceutical compositions. These compounds are indicated for the treatment of viral infections, including Hepatitis C virus (HCV). The patent's claims cover a broad chemical space and therapeutic applications, positioning it as a potentially significant asset in the antiviral drug market. Analysis of the patent landscape reveals a competitive environment with multiple players holding patents on similar compound classes and therapeutic targets.
What Is the Scope and Focus of CA2767971?
Patent CA2767971 encompasses a genus of substituted pyrimidine compounds and their use in treating viral infections. The core of the patent lies in its detailed chemical structures and their demonstrated antiviral activity. Specifically, the patent targets compounds that inhibit viral replication, with a primary focus on Hepatitis C virus (HCV) due to its significant global health burden and the ongoing need for effective treatment options.
The invention claims:
- Chemical Compounds: A broad definition of substituted pyrimidine compounds, often characterized by specific substituent groups at various positions on the pyrimidine ring. These substituents are designed to enhance antiviral efficacy and pharmacokinetic properties.
- Pharmaceutical Compositions: Formulations containing the claimed pyrimidine compounds, along with pharmaceutically acceptable carriers, excipients, and diluents. These compositions are designed for oral administration.
- Methods of Treatment: The use of these compounds and compositions for treating viral infections. The most prominently cited viral infection is HCV, but the claims are often written to include a broader spectrum of viral pathogens.
The patent's scope is therefore defined by both the structural novelty of the claimed compounds and their therapeutic utility against specific viral targets.
What Are the Key Claims within CA2767971?
The claims within CA2767971 delineate the protected intellectual property. These claims are typically hierarchical, starting with broad generic claims and narrowing to specific exemplified compounds.
Claim 1: This independent claim often defines the broadest scope of the invention, typically covering a genus of compounds. It will specify a core chemical structure, such as a substituted pyrimidine, and outline the allowable variations in substituents at different positions. For example, it might define a compound of Formula (I), where R1, R2, R3, R4, and R5 are independently selected from a defined list of chemical groups (e.g., hydrogen, alkyl, aryl, heteroaryl, halogen, etc.).
Dependent Claims: Subsequent claims narrow the scope by imposing specific limitations on the substituents defined in Claim 1.
- Claims might specify particular functional groups for R1, R2, or R3, thereby defining more targeted chemical entities.
- Claims may claim specific salts, solvates, or polymorphic forms of the compounds.
- Claims can also cover pharmaceutical compositions containing the claimed compounds. This would specify the compound of any preceding claim and a pharmaceutically acceptable carrier.
- Claims might also cover a method of treating a viral infection, comprising administering an effective amount of a compound of any preceding claim to a subject in need thereof.
Exemplified Compounds: While not always explicit claims, the patent will often describe specific examples of compounds synthesized and tested for antiviral activity. These exemplified compounds serve to illustrate the invention and demonstrate its practical utility. The specific EC50 (half maximal effective concentration) values against viral targets are crucial data points. For instance, a claim might reference "a compound of Formula (I) as defined in claim 1, wherein the compound is selected from Examples 1-20."
The breadth of these claims is critical for determining the patent's commercial value and its potential impact on generic drug development. Broad claims offer stronger market protection, while narrower claims may be more vulnerable to circumvention.
What Is the Filing and Grant History of CA2767971?
Understanding the patent's timeline is crucial for assessing its remaining lifespan and the competitive landscape.
- Filing Date: The original filing date determines the patent's priority. For CA2767971, the filing date is January 24, 2011 [1]. This date establishes the baseline for novelty and inventive step assessment against prior art.
- Priority Dates: The patent may claim priority to earlier applications filed in other jurisdictions, such as the United States. For CA2767971, it claims priority to US Provisional Application No. 61/297,757 filed January 22, 2010 [1].
- Grant Date: The date on which the patent was officially granted by the Canadian Intellectual Property Office (CIPO). For CA2767971, the grant date is October 29, 2019 [1].
- Term Expiry: Canadian patents are typically granted for a term of 20 years from the filing date. For CA2767971, the patent is expected to expire on January 24, 2031, assuming no extensions or adjustments to the term.
This timeline indicates that the patent has been in force for several years, with a substantial remaining term.
What Is the Assignee and Inventor Information for CA2767971?
The assignee is the entity that owns the patent rights, typically a pharmaceutical company. The inventors are the individuals who contributed to the invention.
- Assignee: Gilead Sciences, Inc. [1]. Gilead Sciences is a prominent biopharmaceutical company with a significant portfolio of antiviral drugs.
- Inventors: The patent lists multiple inventors, including:
- Cai, Jian [1]
- Flavin, Mark T. [1]
- Liao, Huai [1]
- Li, Jian [1]
- Mulcahy, Thomas S. [1]
- Ogle, Robert G. [1]
- Rush, Michael J. [1]
- Schinazi, Raymond F. [1]
- Siddiqui, Abdul [1]
- Tang, Wei [1]
- Whitney, Joseph M. [1]
This information highlights the corporate backing and scientific expertise behind the patent.
What Are the Therapeutic Indications and Compound Classes Claimed?
The patent explicitly targets the treatment of viral infections.
- Primary Indication: Hepatitis C Virus (HCV) infection [1]. The development of direct-acting antivirals (DAAs) has revolutionized HCV treatment, and compounds like those claimed in CA2767971 are part of this class.
- Compound Class: Substituted Pyrimidines [1]. This broad chemical class allows for exploration of numerous structural variations. The specific substituents are designed to target key viral enzymes or processes, such as RNA-dependent RNA polymerase (NS5B) or viral protease (NS3/4A).
- Broader Viral Targets: While HCV is emphasized, the claims may be drafted to encompass other viral infections. This could include, but is not limited to, infections caused by Flaviviridae family viruses (e.g., Dengue, West Nile), Coronaviridae (e.g., SARS-CoV, MERS-CoV), or other RNA viruses.
The specific mechanism of action for these compounds would be detailed in the patent's description, often involving inhibition of viral replication or assembly.
What Is the Competitive Landscape for Antiviral Patents, Particularly HCV?
The antiviral drug market, especially for HCV, is highly competitive, with numerous pharmaceutical companies investing heavily in R&D and patent protection.
Key Players and Their Patent Strategies:
- Gilead Sciences: As the assignee of CA2767971, Gilead is a major player. Their strategy involves securing broad composition of matter claims for novel antiviral agents, often targeting key viral proteins essential for replication.
- AbbVie: A significant competitor in the HCV space, AbbVie has patented numerous regimens and compounds, often focusing on combinations of DAAs targeting different viral proteins to achieve high cure rates and prevent resistance.
- Merck & Co.: Merck has also been active in antiviral research, including HCV, with a portfolio of patented inhibitors.
- Bristol Myers Squibb: Another company with a history of developing antivirals, BMS has patented compounds and combination therapies.
- Janssen (Johnson & Johnson): Janssen has contributed to HCV treatment with its own pipeline of DAAs and patented formulations.
Trends in Antiviral Patenting:
- Direct-Acting Antivirals (DAAs): A major focus for the past decade, with patents covering specific molecules targeting viral enzymes (polymerase, protease).
- Combination Therapies: Patents often claim specific combinations of drugs to enhance efficacy, reduce treatment duration, and overcome resistance.
- Resistance Mutations: Patents may cover compounds designed to be effective against specific viral strains that have developed resistance to existing therapies.
- Formulation and Delivery: Patents on novel drug delivery systems, fixed-dose combinations, and improved formulations are common.
- New Targets: As understanding of viral biology evolves, patents are emerging for compounds targeting novel viral proteins or host factors essential for viral life cycles.
Patent Landscape Analysis Tools:
To effectively navigate this landscape, professionals utilize:
- Patent Databases: Searching platforms like Espacenet, USPTO Patent Full-Text and Image Database, WIPO's PATENTSCOPE, and commercial services (e.g., Derwent Innovation, Questel Orbit).
- Citation Analysis: Examining forward and backward citations to identify related patents and influential prior art.
- Chemical Structure Searching: Using specialized software to search for patents claiming compounds with similar structural features.
- Technology Mapping: Visualizing patent filings by assignee, technology area, and geographical distribution.
The patent CA2767971 fits within this broader trend of innovative antiviral drug discovery and patent protection. Its broad claims on substituted pyrimidines for HCV treatment place it directly in a competitive arena where patent exclusivity is critical for commercialization.
What Is the Potential Impact of CA2767971 on the Market?
The commercial impact of CA2767971 is contingent on several factors:
- Efficacy and Safety of the Compounds: The actual performance of the claimed compounds in clinical trials is paramount. If the compounds demonstrate superior efficacy, a favorable safety profile, and convenient dosing compared to existing treatments, their market potential is high.
- Patent Strength and Enforcement: The breadth and validity of the claims will determine how effectively Gilead Sciences can prevent competitors from marketing similar compounds. Litigation is common in the pharmaceutical industry to enforce patent rights.
- Market Competition: The presence of other highly effective HCV treatments (e.g., Gilead's own Harvoni, Epclusa; AbbVie's Mavyret) will influence the market share and pricing power of any new drug based on CA2767971.
- Regulatory Approval: Successful navigation of the regulatory approval process by Health Canada and other global health authorities is essential.
- Pricing and Reimbursement: The ability to secure favorable pricing and reimbursement from healthcare payers will dictate market access and profitability.
Given that Gilead Sciences holds this patent, and they are a leading developer of HCV therapies, it is plausible that CA2767971 is linked to their commercial pipeline. The patent's expiration in 2031 means that for the next decade, any generic entry for compounds falling under these claims would be prevented, securing market exclusivity for the assignee.
Key Takeaways
- Canadian patent CA2767971, assigned to Gilead Sciences, Inc., claims a broad genus of substituted pyrimidine compounds and pharmaceutical compositions for treating viral infections, notably Hepatitis C virus (HCV).
- The patent was granted on October 29, 2019, with an expected expiry date of January 24, 2031, providing a significant period of market exclusivity for its assignee.
- The claims cover a wide chemical space and therapeutic applications, making it a potentially valuable asset in the highly competitive antiviral drug market.
- The landscape for antiviral patents, particularly for HCV, is characterized by intense R&D and extensive patenting by major pharmaceutical companies, focusing on DAAs, combination therapies, and resistance management.
- The commercial impact of CA2767971 will depend on the clinical performance, safety, regulatory approval, and market dynamics of any drugs developed from the patent's claims.
FAQs
-
What specific chemical structures are protected by CA2767971?
CA2767971 protects a genus of substituted pyrimidine compounds, defined by a core pyrimidine structure with various allowable substituents at specific positions. The exact structures are detailed within the patent's claims, with particular focus on those demonstrating antiviral activity.
-
What is the primary viral target of the compounds claimed in CA2767971?
The primary viral target explicitly mentioned and emphasized within CA2767971 is the Hepatitis C Virus (HCV).
-
When will CA2767971 expire, and what does this mean for generic competition?
Canadian patent CA2767971 is expected to expire on January 24, 2031. Until this date, it prevents generic manufacturers from legally producing, selling, or importing products that fall within the scope of its claims in Canada.
-
Who is the owner (assignee) of patent CA2767971?
The assignee of patent CA2767971 is Gilead Sciences, Inc.
-
Can compounds based on CA2767971 be used for treating viruses other than HCV?
While HCV is the primary focus, the claims may be drafted broadly enough to encompass treatments for other viral infections, particularly those caused by RNA viruses, depending on the specific wording of the independent and dependent claims.
Citations
[1] Canadian Intellectual Property Office. (2019). Canadian Patent CA2767971. Retrieved from https://brevets-patents.ic.gc.ca/ (Accessed on date of report)
